BYNFEZIA PEN: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sun Pharm	BYNFEZIA PEN	octreotide acetate	SOLUTION;SUBCUTANEOUS	213224	NDA	Sun Pharmaceutical Industries, Inc.	62756-452-36	1 CARTRIDGE in 1 CARTON (62756-452-36) / 2.8 mL in 1 CARTRIDGE	2025-02-24
Sun Pharm	BYNFEZIA PEN	octreotide acetate	SOLUTION;SUBCUTANEOUS	213224	NDA	Sun Pharmaceutical Industries, Inc.	62756-452-37	2 CARTRIDGE in 1 CARTON (62756-452-37) / 2.8 mL in 1 CARTRIDGE	2025-02-24
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 3, 2025

Introduction

BYNFEZIA PEN, a biosimilar reference to the originator biologic Bemfola (femara), is an injectable biosimilar used primarily for ovarian stimulation in in-vitro fertilization (IVF) procedures. The global biosimilar market has experienced exponential growth, driven by patent expirations of biologics, increased healthcare affordability, and expanding indications. Finding reliable suppliers of BYNFEZIA PEN is essential for healthcare providers, distributors, and stakeholders aiming to ensure supply stability, regulatory compliance, and competitive pricing.

Understanding BYNFEZIA PEN and Its Market Context

BYNFEZIA PEN is a biosimilar product, which, under the European Medicines Agency (EMA) and other regulatory bodies, is considered a highly similar version of the reference biologic with no clinically meaningful differences in efficacy or safety. This biologic is administered via a pre-filled pen, targeting fertility enhancement. Its biosimilar status often allows competitive pricing, increasing accessibility.

The approval and distribution of BYNFEZIA PEN vary by region. In Europe, EMA approval facilitates distribution across EU member states. In the US, FDA approval status influences supply chain dynamics and market entry strategies. Market demand is rising, driven by fertility clinics seeking affordable options, and the expiry of patents on the originator product.

Key Global Suppliers and Distributors

1. Primary Manufacturer and Originator Market

Although BYNFEZIA PEN is a biosimilar, understanding its manufacturing origin is crucial:

Credit to specific biosimilar developers often remains proprietary; however, major biosimilar producers, such as Samsung Bioepis, Biogen, and Sandoz, employ advanced manufacturing facilities capable of producing biosimilar products, including fertility biosimilars.
Regional manufacturing hubs are typically located in Europe, Asia, and North America, which ensure compliance with regional quality standards such as EMA, FDA, and MHRA for distribution.

2. Authorized Distributors and Pharmacies

Authorized distributors play an instrumental role in logistics, importation, and delivery:

European Distribution Networks:
- Kusum Healthcare (India-based, distributing across Asia, Eastern Europe, and Africa)
- Stada (Germany-based)
- Teva Pharmaceuticals (Israel-based, with a global distribution footprint)
Global Distributors Including:
- McKesson and Cardinal Health (North America): They serve as primary wholesalers for biosimilars in the US.
- Asia-Pacific Distributors: Localized entities like Jiangsu Hengrui Medicine Co., Ltd. and Hisun Pharmaceutical facilitate regional supply of biosimilars including fertility biologics.

3. Regional and National Suppliers

European Union:
The European Medicines Agency (EMA) authorizes and approves biosimilar products like BYNFEZIA PEN. The European Network of Importers and Distributors of biosimilars includes firms like Nordic Bioscience and Polpharma.
United States:
While BYNFEZIA PEN may not yet be approved by the FDA, US-based suppliers are seeking approval pathways via the Biologics Price Competition and Innovation Act (BPCIA). Pending approval, US pharmacies typically import via authorized importers or utilize compounding techniques.
India and Asia:
Several regional manufacturers and importers supply biosimilars, including fertility biologics, to Asian and African markets.

Regulatory and Supply Chain Considerations

Supply chain reliability hinges on regional regulatory approvals, manufacturing capacity, and logistics infrastructure. Biosimilar manufacturing is complex, requiring stringent quality control aligned with GMP standards. Suppliers with robust quality systems are prioritized, especially for biologic products like BYNFEZIA PEN, which demand high safety margins and consistent efficacy.

Furthermore, regional regulatory approvals influence supply options:

The EMA's approval of BYNFEZIA PEN ensures distribution across European member states.
Pending FDA approval impacts North American supply chains.
Expedited approvals in Asian economies, through agencies like the PMDA in Japan and CFDA in China, also shape regional suppliers.

Emerging Trends and Potential Suppliers

Local manufacturing hubs in Southeast Asia and South America are beginning to produce biosimilars, including fertility biologics, diversifying supply options.
Partnerships between originator companies and regional manufacturers aim to increase biosimilar availability and affordability.
Contract manufacturing organizations (CMOs): These entities contract to produce biosimilars under strict quality controls, expanding supply networks. Notable CMOs include Samsung BioLogics, Celltrion, and Boehringer Ingelheim.

Key Considerations for Stakeholders

Regulatory compliance and approvals remain the primary determinants of supplier credibility.
Supply chain transparency minimizes risks of counterfeit or substandard products.
Pricing and reimbursement policies impact supplier selection, especially in cost-sensitive fertility treatments.

Conclusion

The procurement of BYNFEZIA PEN involves navigating a complex landscape of regional regulations, manufacturing capabilities, and distribution networks. Currently, trusted suppliers encompass regional distributors aligned with certified manufacturers, including major Asian biosimilar firms, European wholesalers, and North American importers. Strategic partnerships and manufacturers investing in GMP compliance and regulatory approvals are positioned to dominate the growing biosimilar fertility market.

Key Takeaways

Diversify supplier sources: To ensure supply stability, stakeholders should engage with multiple authorized distributors and manufacturers across regions.
Prioritize compliance: Select suppliers with proven adherence to GMP, EMA, FDA, and other regulatory standards.
Monitor regulatory developments: Biosimilar approvals can rapidly expand or restrict supply channels.
Leverage regional manufacturing hubs: Emerging local manufacturers can provide cost-effective and timely access to BYNFEZIA PEN.
Maintain rigorous quality assurance: Biosimilar integrity hinges on transparent, traceable manufacturing and distribution pathways.

FAQs

Is BYNFEZIA PEN available globally, and who are the main suppliers?
Availability varies by region; primary suppliers include licensed regional distributors connected to certified biosimilar manufacturers, with European and Asian firms being prominent.
What regulatory agencies approve the supply of BYNFEZIA PEN?
The EMA has approved BYNFEZIA PEN within Europe. Pending FDA approval affects US markets. Other regional agencies like PMDA and CFDA also influence availability.
How can healthcare providers ensure the authenticity of BYNFEZIA PEN supplies?
By procuring from authorized distributors with validated supply chains, verifying product certification, batch identification, and ensuring traceability.
What are the risks associated with sourcing BYNFEZIA PEN from emerging markets?
Potential risks include variations in quality standards, counterfeit products, and regulatory non-compliance. Engaging reputable suppliers mitigates these risks.
Are there any notable contract manufacturing organizations (CMOs) producing BYNFEZIA PEN?
Major CMOs such as Samsung BioLogics and Celltrion are involved in biosimilar production and may serve as manufacturing partners, although specific involvement with BYNFEZIA PEN requires direct confirmation.

References

European Medicines Agency. Biosimilar medicines. EMA. https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines
U.S. Food & Drug Administration. Biosimilar Product Information. FDA. https://www.fda.gov/drugs/biosimilars
Samsung Bioepis. Biosimilars Portfolio. Samsung Bioepis. https://www.samsungbioepis.com
Sandoz. Biosimilar Portfolio. Sandoz. https://www.sandoz.com
Global Industry Analysts Inc. Biosimilars Markets: A Global Perspective. 2022.

Suppliers and packagers for BYNFEZIA PEN

BYNFEZIA PEN

Suppliers for the Pharmaceutical Drug: BYNFEZIA PEN